Leadership & Pay ·
JNJ appoints Tom Cavanaugh to succeed retiring Innovative Medicine head Jennifer Taubert
JNJJohnson & Johnson
Johnson & Johnson announced that Jennifer Taubert will retire from her position as Executive Vice President, Worldwide Chairman of Innovative Medicine and member of the Executive Committee effective September 1, 2026. Tom Cavanaugh, currently Group Chairman for North America in Innovative Medicine, has been appointed to succeed her and will join the Executive Committee on the same date. Under Taubert's leadership, the Innovative Medicine business grew to more than $60 billion in annual revenue. Johnson & Johnson operates as a global healthcare company with segments in innovative medicine and medtech.